Akari Therapeutics Plc Sponsored ADR Stock
Akari Therapeutics Plc Sponsored ADR Stock price
Key metrics
| Market capitalization | $37.04m |
| Enterprise Value | $32.86m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | negative |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-16.75m |
| Free Cash Flow (TTM) Free Cash Flow | $-16.30m |
| Cash position | $4.18m |
Is Akari Therapeutics Plc Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
Akari Therapeutics Plc Sponsored ADR Stock Analysis
Analyst Opinions
1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:
Analyst Opinions
1 Analyst has issued a forecast Akari Therapeutics Plc Sponsored ADR:
Financial data from Akari Therapeutics Plc Sponsored ADR
| Dec '23 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -17 -17 |
-
|
EBIT (Operating Income) EBIT | -17 -17 |
-
|
| Net Profit | -9.95 -9.95 |
-
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Akari Therapeutics Plc Sponsored ADR directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Akari Therapeutics Plc Sponsored ADR Stock News
Company Profile
Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.
| Head office | United Kingdom |
| CEO | Samir Patel |
| Founded | 2004 |
| Website | www.akaritx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
